New research from the University of Michigan has shed light on a pivotal protein, NSD2, and its role in promoting prostate cancer. NSD2 is a histone methyltransferase, a protein responsible for modifying histones—proteins around which DNA is wrapped. This modification influences the accessibility of DNA, ultimately affecting gene expression. In…

Widespread, opportunistic testing for prostate specific antigen (PSA) could be contributing the overdiagnosis of prostate cancer across Europe, researchers warn. Their findings, in The BMJ, have implications for prostate cancer screening programs and initiatives such as Europe’s Beating Cancer Plan. This EU project recently released recommendations from European Commission’s council…

Data from a team of Australian researchers shows the potential of a new therapeutic strategy for treating castration-resistant prostate cancer (CRPC), the most aggressive form of the disease. The research, published in the British Journal of Cancer, studied the role of Cyclin-Dependent Kinase 9 (CDK9) in the progression of aggressive…

One of the common indicators of prostate cancer recurrence is an elevated level of prostate-specific antigen (PSA). When PSA levels begin to rise after treatment, it signals that the cancer may be returning, leading to what is known as biochemically recurrent (BCR) prostate cancer. In recent years, the focus has…

University of Sheffield scientists have discovered a novel form of immunotherapy that utilizes nanoparticles to activate immune cells to kill cancer cells and delays resistance to powerful first-line treatment. This study in mouse and human prostate tumors could help men with prostate cancer to live longer. The findings are published…

Researchers have known for some time that about seven percent of people diagnosed with low-risk prostate cancer following a biopsy actually have the deadly form of the disease. Recently, some experts have called for the lowest grade of prostate cancer—biopsy Gleason Grade Group (GGG) 1—to be reclassified as “benign.” A…

Researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Belgium, have developed a novel liquid biopsy methodology that enables the monitoring of disease evolution in patients with metastatic prostate cancer. The study, published in Cancer Cell, leverages the RNA contained in extracellular vesicles shed by tumor cells into the…

An international study led by the Radboud University Medical Center has demonstrated that artificial intelligence (AI) can detect prostate cancer on MRI scans more effectively than radiologists, while also reducing false positives by half. The findings, published in The Lancet Oncology, mark a significant advancement in the use of AI…

A first-in-man study, by researchers at the Nuffield department of surgical sciences and the department of oncology, at the University of Oxford, Oxford University Hospitals and Oxford NIHR Biomedical Research Center University of Oxford, and at Oxford University Hospitals NHS Trust, demonstrates how a fluorescent marker dye that sticks to…

A City of Hope-developed CAR T cell therapy has shown it is both safe and produced promising therapeutic activity in patients with metastatic castration resistant prostate cancer (mCRPC). Results of the Phase I clinical trial were published today in Nature Medicine. The study treated 14 patients with prostate stem cell…

Applying three-dimensional AI to biopsies could predict the recurrence of prostate cancer better than traditional histopathology, researchers report. Their TriPath 3D pathology deep-learning platform more accurately reflected the intrinsically diverse nature of human tissue and could help guide clinical decisions, according to the findings reported in the journal Cell. The…

Researchers at the University of Michigan Rogel Cancer Center have announced the development of a novel urine-based test named MyProstateScore2.0 (MPS2), aiming to revolutionize the diagnosis of prostate cancer by identifying high-grade cancers that require immediate intervention. Reporting in JAMA Oncology, the new test could significantly decrease the number of…

Researchers from the Brigham and Women’s Hospital, drawing on a range of research studies of prostate cancer, report that a diagnostic approach combining both MRI with prostate-specific antigen (PSA) density can help doctors avoid performing unnecessary prostate biopsies. The results, published last week in JAMA Network Open provides a new…

A U.K. study has shown that prostate cancer can be classified into two distinct prostate cancer subtypes according to how gene mutations evolve within the tumors, with one type linked to more aggressive disease than the other. The discovery was made by an international team, led by the University of…

New research has revealed that the receptor protein known as CHRM1 was identified as a key driver for docetaxel-resistant prostate cancer. Led by a team of scientists at Washington State University, the study showed that inhibiting CHRM1 restored docetaxel’s ability to kill cells and stop tumor growth. The researchers suggest…